{"input_url":"https://www.bioxconomy.com/modalities/peptide-therapy-triumphs-in-phase-i-parkinson-s-trials","gnews_decode":"https://www.bioxconomy.com/modalities/peptide-therapy-triumphs-in-phase-i-parkinson-s-trials","http_status":200,"final_url":"https://www.bioxconomy.com/modalities/peptide-therapy-triumphs-in-phase-i-parkinson-s-trials","html_length":353878,"trafilatura_result":"ok","text_length":2930,"text_preview":"Earlier this month, Denmark-based biotechnology company Teitur Trophics announced positive Phase I clinical trial results (2025-521357-17-00) for its therapeutic peptide, TT-P34. The drug triggers a neuroprotective benefit when exposed to the central nervous system (CNS).\n“One of the hardest parts o","verdict":"OK"}